Ritonavir News and Research

RSS
Ritonavir, also known as Norvir, is a type of medicine called a protease inhibitor (PI). PIs act by blocking protease, a protein that HIV needs to make more copies of itself. Ritonavir was approved by the FDA on March 1, 1996, for use with other antiretroviral agents in the treatment of HIV infection in adults and children 2 years of age or older. Ritonavir is now approved with other anti-HIV drugs in the treatment of HIV-1 infection in children in individuals over 1 month in age. Studies have shown that ritonavir works as a booster for some other PIs. Taking ritonavir makes it possible to take a lower dose of the other PIs. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.
Clinical data on simeprevir for treatment of hepatitis C patients to be presented at EASL meeting

Clinical data on simeprevir for treatment of hepatitis C patients to be presented at EASL meeting

FDA accepts Merck's NDA for NOXAFIL tablets

FDA accepts Merck's NDA for NOXAFIL tablets

Phase 3 study results of simeprevir in hepatitis C patients to be presented at EASL Congress

Phase 3 study results of simeprevir in hepatitis C patients to be presented at EASL Congress

Abstracts on Bristol-Myers Squibb's research in liver disease accepted for presentation

Abstracts on Bristol-Myers Squibb's research in liver disease accepted for presentation

Medivir seeks FDA approval for simeprevir

Medivir seeks FDA approval for simeprevir

Indonesia to issue compulsory licenses for HIV, hepatitis B drugs still under patent

Indonesia to issue compulsory licenses for HIV, hepatitis B drugs still under patent

Discovery provides clues for potentially eliminating HIV infection in children

Discovery provides clues for potentially eliminating HIV infection in children

HCV and HIV co-infected patients achieve early treatment success with faldaprevir, PegIFN/RBV

HCV and HIV co-infected patients achieve early treatment success with faldaprevir, PegIFN/RBV

Janssen submits simeprevir regulatory application in Japan to treat HCV

Janssen submits simeprevir regulatory application in Japan to treat HCV

Gilead Sciences fourth quarter total revenues increase 18% to $2.59 billion

Gilead Sciences fourth quarter total revenues increase 18% to $2.59 billion

Janssen, Medivir and Idenix partner for clinical development of HCV combination therapy

Janssen, Medivir and Idenix partner for clinical development of HCV combination therapy

Gilead commences first of two tenofovir alafenamide Phase 3 trials in HIV

Gilead commences first of two tenofovir alafenamide Phase 3 trials in HIV

Janssen receives EC approval for PREZISTA 800mg tablet to treat HIV

Janssen receives EC approval for PREZISTA 800mg tablet to treat HIV

Bristol-Myers Squibb, Pfizer receive FDA approval for ELIQUIS to reduce risk of stroke and SE

Bristol-Myers Squibb, Pfizer receive FDA approval for ELIQUIS to reduce risk of stroke and SE

Top-line results from Medivir's simeprevir phase III trials on genotype 1 HCV infection

Top-line results from Medivir's simeprevir phase III trials on genotype 1 HCV infection

Medivir commences cohort 2 simeprevir and sofosbuvir phase II combination trial in HCV GT1

Medivir commences cohort 2 simeprevir and sofosbuvir phase II combination trial in HCV GT1

Janssen receives positive opinion from EMA CHMP for ZYTIGA to treat mCRPC

Janssen receives positive opinion from EMA CHMP for ZYTIGA to treat mCRPC

Abbott releases details on phase 3 hepatitis C registrational program

Abbott releases details on phase 3 hepatitis C registrational program

Phase II study to evaluate Medivir/Janssen's simeprevir and Vertex against HCV

Phase II study to evaluate Medivir/Janssen's simeprevir and Vertex against HCV

Janssen, Vertex to evaluate TMC435 and VX-135 in Phase 2 HCV study

Janssen, Vertex to evaluate TMC435 and VX-135 in Phase 2 HCV study